Tranexamic Acid Overdose & Accidental Excess Dose: What Every Woman Needs to Know

What Is Tranexamic Acid and How Does It Work?

Tranexamic acid is an antifibrinolytic drug. It slows bleeding by blocking the breakdown of fibrin clots that your body has already formed. The mechanism is straightforward: TXA binds competitively to lysine-binding sites on plasminogen, preventing plasminogen from attaching to fibrin and converting into plasmin, the enzyme that dissolves clots. With plasmin activity suppressed, existing clots stay intact longer, and bleeding slows or stops.

That single mechanism explains why TXA is used across a wide range of bleeding situations, from heavy menstrual bleeding (HMB) to surgical blood loss to trauma. For women, the two most common exposures are oral TXA for HMB and topical TXA for melasma.

The Two Female-Specific FDA-Recognized Indications

Heavy menstrual bleeding. The FDA approved oral tranexamic acid (Lysteda, 650 mg tablets) for HMB in 2009. The approved dose is 1,300 mg (two 650 mg tablets) taken three times daily for a maximum of five days during menstruation. That is 3,900 mg per day. Taking more than this prescribed schedule, or taking TXA on non-bleeding days of your cycle, counts as excess dosing.

Melasma. Off-label oral TXA and compounded topical TXA (typically 3-10%) are used for melasma, a condition affecting predominantly women and driven heavily by estrogen exposure. A 2019 meta-analysis found oral TXA produced statistically significant reductions in MASI (Melasma Area and Severity Index) scores compared with placebo, though the evidence base is still growing. Oral doses for melasma (commonly 250 mg twice daily) are lower than HMB doses, which matters for overdose calculations.

Why Women Are More Exposed to This Drug Than Men

Women are the primary users of oral TXA. HMB affects approximately 1 in 5 women of reproductive age, melasma affects up to 6 million women in the United States, and postpartum hemorrhage protocols increasingly include TXA as a first-line agent. Understanding overdose risk is not an abstract pharmacology question for most women who take this drug. It is a practical safety concern.

What Counts as an Overdose or Accidental Excess Dose?

An overdose is not just a dramatic, intentional ingestion. Most accidental excess doses happen in three patterns.

Pattern 1: Dosing Errors With Oral TXA for HMB

The maximum approved daily dose for HMB is 3,900 mg/day for no more than 5 consecutive days. Common errors include:

• Taking three tablets instead of two at each dosing time (4,350 mg/day rather than 3,900 mg/day)
• Continuing for 7 or 8 days instead of stopping at day 5
• Doubling up because of a missed dose (not recommended, just skip and continue the schedule)

Pattern 2: Combining Oral Doses for Melasma With Additional TXA

Women receiving low-dose oral TXA (250 mg twice daily) for melasma who are also prescribed TXA for a bleeding episode may inadvertently stack doses. Because melasma prescribing often happens through dermatology or aesthetics channels, the prescriber may not know about a concurrent gynecology prescription.

Pattern 3: High-Dose IV TXA in Hospital Settings

If you are hospitalized for postpartum hemorrhage or surgery, TXA may be given intravenously. The WOMAN trial demonstrated that 1 g IV TXA given within 3 hours of childbirth reduced death from postpartum hemorrhage, but dosing in hospital is weight- and context-adjusted. Errors at this level are the responsibility of the clinical team, not the patient.

Signs and Symptoms of Tranexamic Acid Overdose

No confirmed lethal oral dose in humans has been established in the published literature. Toxicity data comes largely from high-dose IV use in cardiac surgery and animal studies. Excess TXA produces a recognizable toxidrome with two main axes: neurological and thrombotic.

Neurological Symptoms: Seizures Are the Most Serious

Seizures are the most clinically significant overdose effect. TXA crosses the blood-brain barrier and inhibits glycine and GABA-A receptors at high concentrations, which is a pro-convulsant mechanism that is well-documented in cardiac surgery literature where high IV doses are standard. Seizure risk is dose-dependent.

In oral overdose, neurological symptoms may progress in this order:

1. Lightheadedness, dizziness
2. Headache and visual disturbance (color vision changes, blurring)
3. Tinnitus
4. Confusion or agitation
5. Tonic-clonic seizures

If you experience any visual changes or new-onset confusion after taking TXA, treat this as an emergency.

Thrombotic Symptoms: Blood Clots Are a Real Risk

Because TXA blocks fibrinolysis, excess dosing tilts your coagulation balance toward clot formation. Thrombotic events reported with TXA include deep vein thrombosis, pulmonary embolism, and central venous or arterial thrombosis. Symptoms to watch for:

• Calf pain, redness, or swelling (possible DVT)
• Sudden shortness of breath or chest pain (possible PE)
• One-sided weakness, facial drooping, or speech changes (possible stroke)
• Sudden severe headache

Call 911 immediately for any of these. Do not wait to call your prescriber first.

Gastrointestinal Symptoms

At standard doses, GI side effects are common and include nausea, vomiting, diarrhea, and abdominal cramping. With excess dosing these symptoms worsen. Vomiting after an oral overdose may actually reduce the total absorbed dose, which may be favorable.

Immediate Steps If You Have Taken Too Much

1. Call Poison Control: 1-800-222-1222. Available 24/7. Free. Confidential. They will ask you your weight, the amount taken, and the timing.
2. Do not induce vomiting unless specifically instructed. Poison Control or your emergency provider will guide this decision.
3. If the person is unconscious, seizing, or not breathing, call 911 first.
4. Bring your pill bottle to the emergency department so clinicians know the exact formulation and dose.

There is no specific antidote for TXA overdose. Management is supportive: airway protection, benzodiazepines for seizure control, and anticoagulation for confirmed thrombosis. Hemodialysis can remove TXA because it is renally excreted with low protein binding, and this may be considered in severe cases.

How Risk Changes Across Your Life Stage

Sex hormones directly interact with fibrinolysis. Estrogen upregulates plasminogen activator inhibitor-1 (PAI-1) and suppresses fibrinolysis, while progesterone has a comparatively neutral effect. This means your baseline clotting tendency shifts across your reproductive life, and TXA's pro-coagulant effect sits on top of that variable baseline.

Reproductive Years (Ages 18-40, Not Pregnant)

This is the most common life stage for oral TXA use. Heavy menstrual bleeding peaks in the 30s and early 40s, and melasma is driven by combined oral contraceptive (COC) use and UV exposure in this group.

Critical interaction: combined hormonal contraception. COCs already increase VTE risk by 3-4 fold over baseline. Adding TXA on top of COC use is listed as a contraindication in the Lysteda prescribing information for women with a history of thromboembolism. If you are on the pill and prescribed TXA, your prescriber must weigh this risk explicitly. A progestin-only pill or non-hormonal contraception reduces (though does not eliminate) the concern.

Trying to Conceive

TXA has a theoretical benefit in recurrent implantation failure by reducing intrauterine fibrinolysis and potentially supporting early placentation, but this is off-label and the evidence in humans is limited to small observational studies. If you are actively trying to conceive, discuss timing carefully: continuing TXA into the luteal phase when implantation occurs is not supported by strong data, and stopping it just before ovulation may limit your exposure.

Perimenopause (Typically Ages 45-55)

Perimenopausal women experience erratic ovulation, which causes fluctuating estrogen and progesterone levels. Anovulatory cycles produce unopposed estrogen, which raises endogenous clotting factor levels. At the same time, HMB is extremely common in perimenopause because of this hormonal chaos. Many perimenopausal women are prescribed TXA for HMB during this window.

The risk consideration here: cardiovascular risk rises in perimenopause. Women with hypertension, obesity, or a personal history of migraines with aura should discuss their individual thrombosis risk with their prescriber before starting TXA. Migraines with aura are associated with a doubled risk of ischemic stroke even without TXA.

Post-Menopause

Postmenopausal women rarely need TXA for menstrual bleeding by definition. If postmenopausal bleeding is present, TXA is not a first-line treatment and the bleeding requires investigation for endometrial pathology before any antifibrinolytic is considered. ACOG recommends evaluation of postmenopausal bleeding in all cases. Postmenopausal women who use TXA for melasma (at dermatologist direction) have a higher baseline cardiovascular risk and should be screened accordingly before starting.

PCOS

Women with PCOS have a well-documented prothrombotic coagulation profile, including elevated PAI-1 activity, which is worsened by insulin resistance. This means baseline fibrinolytic capacity is already reduced in many women with PCOS. Adding TXA further suppresses fibrinolysis. If you have PCOS and are prescribed TXA for HMB, your prescriber should screen for metabolic syndrome and consider whether a hormonal approach to HMB (for example, a levonorgestrel IUD) might reduce the need for TXA altogether.

Pregnancy, Lactation, and Contraception

Pregnancy Safety

Tranexamic acid is not formally classified under the old FDA A/B/C/D/X category system following the 2015 Pregnancy and Lactation Labeling Rule (PLLR), but historical animal data placed it in Category B: no evidence of fetal harm in animal studies, but adequate and well-controlled human studies are absent. TXA does cross the placenta. Umbilical cord blood concentrations reach approximately the same level as maternal plasma.

The most studied use in pregnancy is for postpartum hemorrhage. The WOMAN trial (2017) randomized 20,060 women with postpartum hemorrhage to 1 g IV TXA versus placebo and found a significant reduction in death from bleeding (1.5% vs. 1.9%, RR 0.81, 95% CI 0.65-1.00) when given within 3 hours of delivery. This is given after delivery, not during pregnancy itself.

Using oral TXA during the first trimester for early pregnancy bleeding is done in clinical practice in some centers, but human safety data specific to first-trimester exposure is limited. Use in pregnancy should be reserved for situations where the benefit clearly outweighs the risk, and always under direct obstetric supervision.

TXA is not a teratogen based on current evidence, but it is not proven safe in human pregnancy either. Do not take it without explicit guidance from your OB-GYN or maternal-fetal medicine specialist.

Lactation

TXA passes into breast milk in small amounts. Milk-to-plasma ratios are approximately 1%, meaning infant exposure is very low. LactMed and most clinical references consider TXA compatible with breastfeeding when used for short durations, such as the 5-day HMB course. If you are breastfeeding and given IV TXA for postpartum hemorrhage, this is a single-dose emergency context and is not a reason to stop breastfeeding. Topical TXA used for melasma while breastfeeding has negligible systemic absorption and is generally considered safe, though systemic absorption data in lactating women is sparse.

Contraception Requirements

TXA is not a teratogen requiring mandatory contraception the way methotrexate or isotretinoin do. However:

• If you are taking TXA and using combined hormonal contraception, your prescriber must assess your individual VTE risk before continuing both.
• If you are taking low-dose TXA for melasma long-term, consider switching from a COC to a progestin-only or non-hormonal method to minimize stacked clot risk.
• There is no contraindication to TXA with progestin-only pills, the hormonal IUD, the copper IUD, or barrier methods.

Who This Drug Is Right For, and Who Should Be Cautious

Well-Suited

• Women aged 18-50 with confirmed heavy menstrual bleeding and no personal or first-degree family history of VTE
• Women with melasma refractory to topical hydroquinone alone, using a low-dose oral or topical TXA protocol
• Women with postpartum hemorrhage in a hospital setting (IV protocol under clinical supervision)
• Women with HMB who want a non-hormonal option (TXA does not affect ovulation or fertility)

Use With Caution or Avoid

• Personal history of DVT, PE, or arterial thrombosis
• Active combined hormonal contraceptive use (COC, patch, ring) without explicit prescriber acknowledgment of the interaction
• Renal impairment: TXA is renally cleared, and dose reduction is required for women with creatinine above 1.4 mg/dL
• Subarachnoid hemorrhage: paradoxically, TXA has been trialed in SAH but is not standard of care and carries its own risk profile
• Women with a history of seizure disorders (neurological threshold is already altered)
• Perimenopause with uncontrolled hypertension or active cardiovascular disease
• First trimester of pregnancy without direct obstetric supervision
• Women with PCOS and insulin resistance who have not been screened for metabolic syndrome

Evidence Gaps Specific to Women

The honest answer is that most TXA overdose data comes from surgical settings where high-dose IV TXA is routine, and those populations skew male (cardiac surgery, orthopedics). Oral TXA overdose in reproductive-age women is not systematically studied. What we know about seizure thresholds and thrombotic risk at supratherapeutic oral doses is largely extrapolated from IV toxicity data and case reports rather than controlled studies in women taking 1,300-3,900 mg/day for HMB.

Specific gaps:

• No pharmacokinetic study has compared oral TXA absorption across menstrual cycle phases. Estrogen affects hepatic protein expression and renal clearance, and TXA pharmacokinetics during the follicular versus luteal phase has not been formally characterized in peer-reviewed literature.
• Melasma dosing safety data in women over 50 is thin. Most melasma TXA trials enrolled women under 50 without significant cardiovascular comorbidities. Dermatologists prescribing off-label TXA to older perimenopausal or early postmenopausal women are extrapolating from younger cohorts.
• Long-term oral TXA safety (beyond 6 months) for HMB or melasma has not been established in randomized trials. The 2019 melasma meta-analysis covered treatment durations of 8-24 weeks; the cumulative thrombotic risk with multi-year use is unknown.

As Dr. Rachel Goldberg, MD, WomanRx editorial board reviewer, notes: "When a woman calls about taking an extra TXA tablet or extending her cycle by two days, the conversation needs to cover not just the dose arithmetic but her contraceptive method, her migraine history, and whether she has any undiagnosed thrombophilia risk factors sitting underneath. The drug looks simple but the individual risk profile is not."

Drug Interactions Relevant to Women Taking TXA

| Drug or Class | Interaction | Clinical Relevance | |---|---|---| | Combined oral contraceptives | Additive thrombotic risk | Contraindicated with personal VTE history; otherwise prescriber judgment | | Factor IX complex concentrates | Risk of thrombosis; avoid combination | Rare but serious | | All-trans retinoic acid (tretinoin, isotretinoin) | No direct PK interaction, but both used for melasma/acne; isotretinoin is teratogenic and requires separate contraception | Co-prescribing common in aesthetics | | NSAIDs | No direct interaction, but NSAIDs can worsen GI bleeding that TXA might be masking | Monitor | | Hormonal IUD (levonorgestrel) | No known interaction; actually preferred co-therapy for HMB because it reduces bleeding through a separate mechanism | Favorable combination |

Topical TXA for Melasma: A Separate Overdose Profile

Topical TXA (applied to skin as a cream or serum at 3-10% concentration) has a fundamentally different systemic absorption profile than oral TXA. Percutaneous absorption is low, and systemic plasma levels after topical application are a fraction of those from oral dosing. Overdose from topical use alone is not a clinically recognized entity.

Concerns with topical TXA are different:

• Skin irritation, particularly with higher concentrations (>5%)
• Contact dermatitis in sensitive skin
• Interaction with other depigmenting agents (niacinamide, hydroquinone, kojic acid) can produce additive irritation but not systemic toxicity

If you accidentally apply a larger amount of topical TXA than directed, rinse the area thoroughly with water. Systemic toxicity from a single topical over-application is not expected based on the pharmacokinetic profile.

Questions Women Ask About TXA Overdose